<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Development of Patient-Derived Xenograft Models for Small Cell Lung Cancer as a Preclinical Platform for Drug Development

Small cell lung cancer comprises 15-20% of all lung cancer cases, and is more invasive and has a higher rate of proliferation than non-small cell lung cancer, leading to a higher mortality rate.